Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway

British Journal of Pharmacology

Volumn 165, Issue 5, 2012, Pages 1390-1400

  Akhtar, Saghir ^a   Yousif, Mariam H M ^a   Dhaunsi, Gursev S ^a   Chandrasekhar, Bindu ^a   Al Farsi, Omama ^a   Benter, Ibrahim F ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

diabetes; hyperglycaemia; streptozotocin; vascular dysfunction; vascular smooth muscle cells

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANGIOTENSIN II; ANGIOTENSIN[1-7]; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOSE; MAS RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN TYROSINE KINASE; RECEPTOR; STREPTOZOCIN; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENTERY BLOOD VESSEL; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TRANSACTIVATION; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; BODY WEIGHT; DIABETES MELLITUS; GLUCOSE; HYPERGLYCEMIA; MALE; MAP KINASE SIGNALING SYSTEM; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RATS; RATS, WISTAR; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TRANSCRIPTIONAL ACTIVATION; TYRPHOSTINS;

EID: 84857096748     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01613.x     Document Type: Article

References (51)

1. Abdallah RT, Keum JS, Lee MH, Wang B, Gooz M, Luttrell DK, et al,. (2010). Plasma kallikrein promotes epidermal growth factor receptor transactivation and signaling in vascular smooth muscle through direct activation of protease-activated receptors. J Biol Chem 285: 35206-35215.
2. Al-Maghrebi M, Benter IF, Diz DI, (2009). Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats. Pharmacol Res 59: 263-268.
3. Almendro V, García-Recio S, Gascõn P, (2010). Tyrosine kinase receptor transactivation associated to G protein-coupled receptors. Curr Drug Targets 11: 1169-1180.
4. Anand-Apte B, Ebrahem Q, Cutler A, Farage E, Sugimoto M, Hollyfield J, et al,. (2010). Betacellulin induces increased retinal vascular permeability in mice. PLoS ONE 5: e13444.
5. Andrew A, Kathryn JW, Alison JC, Yuan Z, Richard EG, Darren JK, (2011). Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy. Nephrology (Carlton) 16: 573-581.
6. Avraham R, Yarden Y, (2011). Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol 12: 104-117.
7. Belmadani S, Palen DI, Gonzalez-Villalobos RA, Boulares HA, Matrougui K, (2008). Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice. Diabetes 57: 1629-1637.
8. Benter IF, Diz DI, Ferrario CM, (1993). Cardiovascular actions of angiotensin-(1-7). Peptides 14: 679-684.
9. Benter IF, Ferrario CM, Morris M, Diz DI, (1995). Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol 269: H313-H319.
10. Benter IF, Yousif MH, Griffiths SM, Benboubetra M, Akhtar S, (2005a). Epidermal growth factor receptor tyrosine kinase-mediated signalling contributes to diabetes-induced vascular dysfunction in the mesenteric bed. Br J Pharmacol 145: 829-836.
11. Benter IF, Yousif MH, Hollins AJ, Griffiths SM, Akhtar S, (2005b). Diabetes-induced renal vascular dysfunction is normalized by inhibition of epidermal growth factor receptor tyrosine kinase. J Vasc Res 42: 284-291.
12. Benter IF, Yousif MH, Anim JT, Cojocel C, Diz DI, (2006). Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol 290: H684-H691.
13. Benter IF, Yousif MH, Cojocel C, Al-Maghrebi M, Diz DI, (2007). Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol 292: H666-H672.
14. Benter IF, Yousif MH, Dhaunsi GS, Kaur J, Chappell MC, Diz DI, (2008). Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol 28: 25-33.
15. Benter IF, Benboubetra M, Hollins AJ, Yousif MH, Canatan H, Akhtar S, (2009a). Early inhibition of EGFR signaling prevents diabetes-induced up-regulation of multiple gene pathways in the mesenteric vasculature. Vascul Pharmacol 51: 236-245.
16. Benter IF, Canatan H, Benboubetra M, Yousif MH, Akhtar S, (2009b). Global upregulation of gene expression associated with renal dysfunction in DOCA-salt-induced hypertensive rats occurs via signaling cascades involving epidermal growth factor receptor: a microarray analysis. Vascul Pharmacol 51: 101-109.
17. Benter IF, Yousif MH, Al-Saleh FM, Raghupathy R, Chappell MC, Diz DI, (2011). Angiotensin-(1-7) blockade attenuates captopril- or hydralazine-induced cardiovascular protection in spontaneously hypertensive rats treated with NG-nitro-L-arginine methyl ester. J Cardiovasc Pharmacol 57: 559-567.
18. Cai Z, Zhang H, Liu J, Berezov A, Murali R, Wang Q, et al,. (2010). Targeting erbB receptors. Semin Cell Dev Biol 21: 961-966.
19. Chappell MC, (2007). Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertension 50: 596-599.
20. Ciardiello F, Tortora G, (2008). EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174.
21. Dhaunsi GS, Hassid A, (1996). Atrial and C-type natriuretic peptides amplify growth factor activity in primary aortic smooth muscle cells. Cardiovasc Res 31: 37-47.
22. Dhaunsi GS, Yousif MH, Akhtar S, Chappell MC, Diz DI, Benter IF, (2010). Angiotensin-(1-7) prevents diabetes-induced attenuation in PPAR-gamma and catalase activities. Eur J Pharmacol 638: 108-114.
23. Egan BM, Lu G, Greene EL, (1999). Vascular effects of non-esterified fatty acids: implications for the cardiovascular risk factor cluster. Prostaglandins Leukot Essent Fatty Acids 60: 411-420.
24. Ferrario CM, Ahmad S, Joyner J, Varagic J, (2010). Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7). Adv Pharmacol 59: 197-233.
25. Gava E, Samad-Zadeh A, Zimpelmann J, Bahramifarid N, Kitten GT, Santos RA, et al,. (2009). Angiotensin-(1-7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells. Nephrol Dial Transplant 24: 1766-1773.
26. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al,. (2008). Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545-2559.
27. Giani JF, Muñoz MC, Pons RA, Cao G, Toblli JE, Turyn D, et al,. (2011). Angiotensin-(1-7) reduces proteinuria and diminishes structural damage in renal tissue of stroke-prone spontaneously hypertensive rats. Am J Physiol Renal Physiol 300: F272-F282.
28. Gilbert RE, Huang Q, Thai K, Advani SL, Lee K, Yuen DA, et al,. (2011). Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor. Kidney Int 79: 1312-1321.
29. Gwathmey TM, Pendergrass KD, Reid SD, Rose JC, Diz DI, Chappell MC, (2011). Angiotensin-(1-7)-angiotensin-converting enzyme 2 attenuates reactive oxygen species formation to angiotensin II within the cell nucleus. Hypertension 55: 166-171.
30. Hayashi N, Yamamoto K, Ohishi M, Tatara Y, Takeya Y, Shiota A, et al,. (2010). The counterregulating role of ACE2 and ACE2-mediated angiotensin 1-7 signaling against angiotensin II stimulation in vascular cells. Hypertens Res 33: 1182-1185.
31. Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S, (2007). Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 112: 417-428.
32. Hollins AJ, Omidi Y, Benter IF, Akhtar S, (2007). Toxicogenomics of drug delivery systems: exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. J Drug Target 15: 83-88.
33. Hussain M, Shchepinov M, Sohail M, Benter IF, Hollins AJ, Southern EM, et al,. (2004). A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides. J Control Release 99: 139-155.
34. Iwai M, Horiuchi M, (2009). Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens Res 32: 533-536.
35. Iyer SN, Ferrario CM, Chappell MC, (1998). Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 31: 356-361.
36. Izzo JL Jr, Zion AS, (2011). Value of angiotensin receptor blocker therapy in diabetes. J Clin Hypertens (Greenwich) 13: 290-295.
37. Kristensen K, Pedersen SB, Vinter-Jensen L, Flyvbjerg A, Richelsen B, (1998). Systemic administration of epidermal growth factor reduces fat mass in rats: effects on the hormone-sensitive-lipase, lipoprotein lipase and leptin. Horm Res 50: 292-296.
38. Liebmann C, (2011). EGF receptor activation by GPCRs: a universal pathway reveals different versions. Mol Cell Endocrinol 331: 222-231.
39. Moon JY, Tanimoto M, Gohda T, Hagiwara S, Yamazaki T, Ohara I, et al,. (2011). Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-Ay/Ta mice. Am J Physiol Renal Physiol. doi:10.1152/ajprenal.00065.2010. [Epub ahead of print].
40. Muthalif MM, Benter IF, Karzoun N, Fatima S, Harper J, Malik KU, (1998). 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proc Natl Acad Sci USA 95: 12701-12706.
41. Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, et al,. (2010). Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59: 529-538.
42. Panchapakesan U, Pollock C, Saad S, (2011). Renal epidermal growth factor receptor: its role in sodium and water homeostasis in diabetic nephropathy. Clin Exp Pharmacol Physiol 38: 84-88.
43. Pedersen SB, Kristensen K, Bruun JM, Flyvbjerg A, Vinter-Jensen L, Richelsen B, (2000). Systemic administration of epidermal growth factor increases UCP3 mRNA levels in skeletal muscle and adipose tissue in rats. Biochem Biophys Res Commun 279: 914-919.
44. Petch AK, Sohail M, Hughes MD, Benter I, Darling J, Southern EM, et al,. (2003). Messenger RNA expression profiling of genes involved in epidermal growth factor receptor signalling in human cancer cells treated with scanning array-designed antisense oligonucleotides. Biochem Pharmacol 66: 819-830.
45. Smith NJ, Chan HW, Qian H, Bourne AM, Hannan KM, Warner FJ, et al,. (2011). Determination of the exact molecular requirements for type 1 angiotensin receptor epidermal growth factor receptor transactivation and cardiomyocyte hypertrophy. Hypertension 57: 973-980.
46. Stegbauer J, Potthoff S, Quack I, Mergia E, Clasen T, Friedrich S, et al,. (2011). Chronic treatment with angiotensin-(1-7) improves renal endothelial dysfunction in apolipoproteinE-deficient mice. Br J Pharmacol 163: 974-983.
47. Tesanovic S, Vinh A, Gaspari TA, Casley D, Widdop RE, (2010). Vasoprotective and atheroprotective effects of angiotensin-(1-7) in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 30: 1606-1613.
48. Ueda S, Masumori-Maemoto S, Ashino K, Nagahara T, Gotoh E, Umemura S, et al,. (2000). Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man. Hypertension 35: 998-1001.
49. Vacaresse N, Lajoie-Mazenc I, Augé N, Suc I, Frisach MF, Nègre-Salvayre A, (1999). Activation of epithelial growth factor receptor pathway by unsaturated fatty acids. Circ Res 85: 892-899.
50. Wassef L, Kelly DJ, Gilbert RE, (2004). Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. Kidney Int 66: 1805-1814.
51. Yousif MH, Benter IF, Akhtar S, (2005). The role of tyrosine kinase-mediated pathways in diabetes-induced alterations in responsiveness of rat carotid artery. Auton Autacoid Pharmacol 25: 69-78.